Novartis’ Entresto Gains US FDA Panel Nod For New Heart Failure Claim

But advisory committee members debate how to define the target population for a new indication, shying away from use of ‘preserved’ to characterize heart failure patients with ejection fraction levels below normal but greater than the definition of ‘reduced’ EF.